BioAI

📣 Exciting Announcement 📣 For the first time, we will be presenting not one, but three posters at the Society for Immunotherapy of Cancer (SITC) conference this year. If you are planning to attend the conference next week, we would love to meet up or see you at one of our poster sessions. Use the link below to schedule a meeting with Thomas Colarusso and Alan Jerusalmi, PhD -- let's discuss how AI-powered pathology can accelerate your cancer research. https://lnkd.in/gS59fXGq

👏 Excellent work 👏 Our CIO, Alan Jerusalmi, PhD, has been busy this month! He will be at SITC next month to discuss AI biomarkers and to present BioAI's recent work.

🎉 We are thrilled to announce strategic collaboration with BioAI in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs). 🎊 We have also entered a strategic alliance with Chime Biologics to accelerate chemistry, manufacturing and control (CMC) process development of the novel designs of ADCs and TCEs. The partnership supports multiple pipelines of about 10 first-in-class and best-in-class immunotherapeutics, including monoclonal, bispecific/biparatopic and TriAx antibodies within the coming 3 years. The collaboration will ensure Arbele continues to have at least 1-2 new molecular entities (NMEs) successfully filing for investigational new drug (IND) application and entering clinical studies in the next 5 years without any technical and supply-chain interruptions. Read more in our press release below. https://lnkd.in/gPGWWR33 #AIoncology #PrecisionMedicine #Immunotherapeutics #Biotech #Diagnostics #CMC #ProcessDevelopment

📣 Our recent partnership with Arbele was picked up by Precision Medicine Online! It's been an exciting week at BioAI 🧬 If you have a subscription, you can read the full story using the link below ⤵️ https://lnkd.in/g97_pwf8

🚀 Exciting News 🚀 We are thrilled to announce a strategic partnership with Arbele to advance predictive AI models in oncology clinical trials. 🤝 This collaboration will harness BioAI's PredictX platform and Arbele’s clinical trial data to drive AI-powered biomarker screening for colorectal cancer (CRC). 🎯 The goal is to create cutting-edge companion diagnostic tests that enhance patient selection and treatment efficacy, revolutionizing personalized medicine for gastrointestinal cancers. 🗣️ As our CEO, Thomas Colarusso, put it: "We are excited to apply our novel AI platform to accelerate the development of innovative treatment options for gastrointestinal cancers. This partnership underscores our commitment to transforming patient care through advanced machine learning." 🧬 Together, we are paving the way for precision medicine breakthroughs to help patients globally with high-mortality cancers. Learn more about this exciting partnership in the full article below! ⤵️

🌍🔬 Today is World Cancer Research Day – a day dedicated to raising awareness about the importance of cancer research and accelerating the fight against cancer. At BioAI, we aim to leverage the power of AI-driven precision biomarkers to transform precision medicine and improve patient outcomes. By harnessing cutting-edge technology, we strive to uncover innovative treatment pathways and enhance the quality of life for patients worldwide. Cancer research is not just about finding a cure—it's about finding better ways to detect, treat, and prevent cancer. As we continue to develop AI-powered solutions, we are proud to contribute to the global fight against cancer and collaborate with the scientific community to accelerate clinical R&D. Together, we can work toward a future where precision medicine transforms the lives of every cancer patient. #WorldCancerResearchDay #BioAI #PrecisionMedicine #CancerResearch #AIBiomarkers #CancerAwareness #Biotech

🔬 BioAI will be at the Bio-Trac® Spatial Biology Symposium next week in Germantown, MD and we hope to see some of you there! About the event: Esteemed experts from pathology, spatial biology, multiplex immunofluorescence, artificial intelligence, and translational medicine explore the latest advancements in the field. Focused on predictive and prognostic models, this gathering offers captivating presentations and insightful discussions.

Heading to World CB & CDx Boston next week? Let's connect! If you would like to meet up with the BioAI team, please use the link below and we can set something up! ⤵ https://lnkd.in/gS59fXGq

🚀 We are thrilled to welcome Jay Foust to the BioAI executive team! 🚀 Jay will be joining our Board of Directors and taking on the new position of Global Head, Dx Strategy. In this role, Jay will be helping to lead our commercial strategy, driving forward our mission to transform precision medicine with multimodal AI. Jay comes with a wealth of experience and an impressive background as the former Executive Director of Business Development at BMS Precision Medicine & Companion Diagnostics. As a biotech executive, he has a proven track record of translating innovative technologies into approved and commercialized medical products. His unique combination of experience in both the pharmaceutical and diagnostic sectors, along with his educational background in molecular biology, finance, pharmaceutical economics, and intellectual property law, makes him an invaluable addition to BioAI. Please join us in welcoming Jay Foust to BioAI! We are excited for the incredible impact he will have here and for the progress we will make together in biomarker development for cancer research. 🌟

Congratulations to the BioAI team and our collaborators at Eli Lilly and Company for the recent publication of our work on RET fusion detection in Lung cancer H&E images, featured in the latest issue of AI in Precision Oncology. This research highlights the potential of BioAI's PredictX platform for patient screening in lung cancer and the promise of this technology for targeted therapy. Thank you to everyone who contributed to this work! Follow the link below for the publication: https://lnkd.in/gEjzT8Rv